The expanded deal – which will allow CRB to make dye-labelled primary antibodies (Ab) in addition to the peptides it already produces – extends the agreement the firms’ established in 2007 through Life Technologies’ Molecular Probes business.
The dyes covered by the new agreement are used label the various Abs and proteins that UK-headquartered CRB produces for drug discovery researchers in academia and the pharmaceutical industry.
Emily Humphrys, CRB’s Commercial Director, said: “We are very pleased with this extension to our licence with Life Technologies as it acknowledges our labelling expertise and strengthens our position in the custom dye labelling market.
“Our customers will not only benefit from our high quality custom antibody service but also the combination of Life Technologies’ universal dyes.”
Paula Stonemetz, Leader of Cell Systems Out licensing and OEM of Life Technologies, said: “We believe a custom antibody specialist company such as CRB are well-placed to offer custom-dye labelled primary antibodies to their existing customer base in Europe.”